Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436 · tracked via the Priya Life Science Italy tracker
Phase
Phase 3
Started
2020-11-26
Last updated
2026-11-10

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

Ocrelizumab →Ocrelizumab →AntihistamineMethylprednisolone →

Ocrelizumab: The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).

Ocrelizumab: Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.

Antihistamine: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.

Methylprednisolone: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.

Study summary

This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of RMS * At least two documented clinical relapses within the last 2 years prior to screening, or one clinical relapse in the year prior to screening. No relapse 30 days prior to screening and at baseline * Participants must be neurologically stable for at least 30 days prior to randomization and baseline * EDSS score, at screening and baseline, from 0 to 5.5 inclusive * Average T25FWT score over two trials at screening and over two trials at baseline respectively, up to 150 (inclusive) seconds * Average 9HPT score over four trials at screening and over four trials at baseline respectively, up to 250 (inclusive) seconds * Documented magnetic resonance imaging (MRI) of brain with abnormalities consistent with MS at screening * Participants requiring symptomatic treatment for MS and/or physiotherapy must be treated at a stable dose. No initiation of symptomatic treatment for MS or physiotherapy within 4 weeks of randomization * Females of childbearing potential, agreement to remain abstinent or use adequate contraceptive methods * Female participants without reproductive potential may be enrolled e.g. if post-menopausal or if surgically sterile Exclusion Criteria: * History of primary progressive MS at screening * Any known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV antimicrobials within 8 weeks or treatment with oral antimicrobials within 2 weeks, prior to and during screening * History of confirmed or suspected progressive multifocal leukoencephalopathy * History of cancer, including hematologic malignancy and solid tumors, within 10 years of screening * Immunocompromised state * Receipt of a live or live-attenuated vaccine within 6 weeks prior to randomization * Inability to complete an MRI or contraindication to gadolinium administration * Contraindications to mandatory pre-medications for infusion-related reaction (IRRs) * Known presence of other neurologic disorders that could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study * Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study * Significant, uncontrolled disease that may preclude participant from participating in the study * History of or currently active primary or secondary, non-drug-related, immunodeficiency * Pregnant or breastfeeding or intending to become pregnant * Lack of peripheral venous access * History of alcohol or other drug abuse within 12 months prior to screening * Treatment with any investigational agent within 24 weeks prior to screening or treatment with any experimental procedure for MS * Previous use of anti- cluster of differentiation 20 (CD20s) (including ocrelizumab), unless the last infusion was more than 2 years before screening, B-cell count is normal, and the stop of the treatment was not motivated by safety reasons or lack of efficacy * Previous treatment with fingolimod, siponimod, or ozanimod within 6 weeks of baseline * Previous treatment with natalizumab within 4.5 months of baseline * Previous treatment with interferons beta (1a or 1b), or glatiramer acetate within 2 weeks of baseline * Any previous treatment with mitoxantrone, cladribine, atacicept, alemtuzumab, and daclizumab - Previous treatment with any other immunomodulatory or immunosuppressive medication not already listed above without appropriate washout as described in the applicable local label. If the washout requirements are not described in the applicable local label, then the wash out period must be five times the half-life of the medication * Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation * Any previous history of transplantation or anti-rejection therapy * Treatment with IV immunoglobulin (Ig) or plasmapheresis within 12 weeks prior to randomization * Systemic corticosteroid therapy within 4 weeks prior to screening * Positive screening tests for active, latent, or inadequately treated hepatitis B * Sensitivity or intolerance to any ingredient (including excipients) of ocrelizumab * Any additional exclusionary criterion as per ocrelizumab local label, if more stringent than the above

Primary outcome measure(s)

  • Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) — Up to approximately 4 years
    Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of the 3 criteria: 1) CDP=12-week confirmed increase (CI) from baseline (FB) in expanded disability status scale (EDSS) score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in Timed 25-foot Walk Test (T25FWT) score OR 3)12-week CI of ≥ 20% FB in 9-hole Peg Test (9-HPT) score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

Trial sites (121)

FacilityCityRegionStatus
North Central Neurology Associates Cullman Alabama
Alabama Neurology Associates Homewood Alabama
21st Century Neurology Phoenix Arizona
Profound Research, LLC Carlsbad California
Stanford University Medical Center Stanford California
Advanced Neurology of Colorado, LLC Fort Collins Colorado
Neurology Associates, PA Maitland Florida
University of South Florida Tampa Florida
American Health Network Institute, LLC Avon Indiana
University of Kansas Medical Center Kansas City Kansas
The NeuroMedical Clinic of Central Louisiana Alexandria Louisiana
Maine Medical Center Scarborough Maine
Dragonfly Research, LLC Wellesley Massachusetts
Henry Ford Health System Detroit Michigan
Washington University School of Medicine St Louis Missouri
Cleveland Clinic Lou Ruvo Las Vegas Nevada
Dent Neurological Institute Amherst New York
UC Health Neurology Dayton Ohio
Oklahoma Medical Research Foundation Oklahoma City Oklahoma
Abington Neurological Associates Willow Grove Pennsylvania
Tri-State Mountain Neurology Johnson City Tennessee
Hope Neurology Knoxville Tennessee
Bhupesh Dihenia M.D. P.A. Lubbock Texas
Lone Star Neurology of San Antonio San Antonio Texas
Evergreen MS Center Kirkland Washington
Centro de Especialidades Neurológicas y Rehabilitación - CENyR Buenos Aires Argentina
CEMIC Buenos Aires Argentina
Centro de Investigaciones Médicas Tucuman San Miguel de Tucumán Argentina
Austin Hospital Heidelberg Victoria
Hospital Erasme Brussels Belgium
Revalidatie en MS Centrum Overpelt Belgium
Instituto de Neurologia de Curitiba Curitiba Paraná
IMV Pesquisa Neurológica Porto Alegre Rio Grande do Sul
Clinica Neurologica Joinville Santa Catarina
CPQuali Pesquisa Clinica Ltda São Paulo São Paulo
Recherche Sepmus Inc. Greenfield Park Quebec
Centre de Recherche Saint-Louis Lévis Quebec
Rigshospitalet Glostrup Glostrup Municipality Denmark
Groupe Hospitalier Pellegrin Bordeaux France
CHU Hopital Gabriel Montpied Clermont-Ferrand France

+ 81 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04544436 on ClinicalTrials.gov ↗ ← All trials in Italy